Contrafect Corporation

Bristol-myers Squibb Compnay

Amgen Inc.

Trellis Bioscience, Inc.

The State University of New York

Aurobac Therapeutics Sas

Michael Wittekind

Raymond Schuch

Yan Chen

Ai Ching Lim

Martin C Wright

Jochem Gokemeijer

Alan S Harris

Lin Sun

Elena Getmanova

Robert C Nowinski

Adam Vigil

Lawrence M Kauvar

Wei Yan

Jimmy Andrew Rotolo

Angeles Estelles

Simon Hoffenberg

Brent Schneider

Babar Khan

Steven Weinheimer

Valentina Goldfarb

Han Lee

Gunasekaran Kannan

Derek Evan Piper

Raymond J Paxton

John M Delaney

Mingyue Zhou

Martin Pentony

Yaqun Zhang

Sarah L Gaffen

Fang Shen

Walter Hanel

Jill Kramer

James P Malone

Carla Forte

Yagun Zhang

David P Meininger

The present disclosure relates to methods for restoring or augmenting bactericidal activity of an antibiotic in an organ or tissue in which pulmonary surfactant is present. More specifically, the present disclosure describes that inhibition of antibiotics due to environmental factors, such as the presence of pulmonary surfactant in an organ or tissue such as the respiratory epithelium can be sidestepped or overcome and the effectiveness of the antibiotic in that milieu restored or augmented by co-administration of an antibiotic and a lysin.

Use of lysin to restore/augment antibacterial activity in the presence of pulmonary surfactant of antibiotics inhibited thereby

The present invention provides methods for treatment or prophylaxis of viruses, particularly influenza virus, by administration of agents, particularly neutralizing antibodies or active fragments thereof, directly to the respiratory tract, including by intranasal or inhalation administration. The invention provides compositions suitable for intranasal or inhalation treatment and administration. The invention includes methods for treatment or prophylaxis combining intranasal or inhalation administration with intraperitoneal or intravenous administration of antibodies.

Composition and methods based on neutralizing antibodies delivered intranasally for enhanced therapeutic efficacy

The present invention provides methods for the prevention, control, disruption and treatment of bacterial biofilms with lysin, particularly lysin having capability to kill Staphlococcal bacteria, including drug resistant, particularly the lysin PlySs2. The invention also provides compositions and methods for use in treatment or modulation of bacterial biofilm(s) and biofilm formation.

Biofilm prevention, disruption and treatment with bacteriophage lysin

The present disclosure provides methods and compositions useful for the prophylactic and therapeutic amelioration and treatment of infections caused by Gram-negative bacteria, including. The disclosure further provides compositions and methods of incorporating and utilizing lysin polypeptides of the present disclosure for augmenting the efficacy of antibiotics generally suitable for the treatment of Gram-negative bacterial infection.

Lysin polypeptides active against Gram-negative bacteria

Antibodies, compositions and methods are provided for treatment and prophylaxis of influenza virus. Antibodies and antigen-binding fragments are provided that hind near the HAmaturation cleavage site consensus sequence of influenza hemagglutinin A. Antibody compositions, combinations and methods for effective passive immunization across influenza A and B strains are also provided.

Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof

The present disclosure relates to novel vascular endothelial growth factor receptor (VEGFR)-binding polypeptides and methods for using these polypeptides to inhibit biological activities mediated by vascular endothelial growth factors (VEGFs). The present disclosure also provides various improvements relating to single domain binding polypeptides.

Libraries of modified fibronectin type III tenth domain-containing polypeptides

The present invention provides compositions and methods for prevention, amelioration and treatment of gram positive bacteria, particularlybacteria, with combinations of lysin, particularly Streptococcal lysin, particularly the lysin PlySs2, and one or more antibiotic, including daptomycin, vancomycin, oxacillin, linezolid, or related antibiotic(s).

Bacteriophage lysin and antibiotic combinations against gram positive bacteria

Antibodies, compositions and methods are provided for treatment and prophylaxis of influenza virus. Antibodies and antigen-binding fragments are provided that bind near the HAmaturation cleavage site consensus sequence of influenza hemagglutinin A. Antibody compositions, combinations and methods for effective passive immunization across influenza A and B strains are also provided.

The present invention provides compositions and methods for prevention, amelioration and treatment of gram positive bacteria, particularly Staphylococcal bacteria, with combinations of lysin, particularly Streptococcal lysin, particularly the lysin PlySs2, and one or more antibiotic, including daptomycin, vancomycin, oxacillin, linezolid, or related antibiotic(s).

Inhibitors of type 2 vascular endothelial growth factor receptors

Growing community of inventors

Bainbridge Island, WA, United States of America

Michael Wittekind